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Abstract
Mammalian Mrp2 and its yeast orthologue, Ycf1p, mediate the ATP-dependent cellular export of a variety of organic
anions. Ycf1p also appears to transport the endogenous tripeptide glutathione (GSH), whereas no ATP-dependent GSH
transport has been detected in Mrp2-containing mammalian plasma membrane vesicles. Because GSH uptake measurements
in isolated membrane vesicles are normally carried out in the presence of 5^10 mM dithiothreitol (DTT) to maintain the
tripeptide in the reduced form, the present study examined the effects of DTT and other sulfhydryl-reducing agents on
Ycf1p- and Mrp2-mediated transport activity. Uptake of S-dinitrophenyl glutathione (DNP-SG), a prototypic substrate of
both proteins, was measured in Ycf1p-containing Saccharomyces cerevisiae vacuolar membrane vesicles and in Mrp2-
containing rat liver canalicular plasma membrane vesicles. Uptake was inhibited in both vesicle systems in a concentration-
dependent manner by DTT, dithioerythritol, and L-mercaptoethanol, with concentrations of 10 mM inhibiting by V40%.
DTT’s inhibition of DNP-SG transport was noncompetitive. In contrast, ATP-dependent transport of [3H]taurocholate, a
substrate for yeast Bat1p and mammalian Bsep bile acid transporters, was not significantly affected by DTT. DTT also
inhibited the ATP-dependent uptake of GSH by Ycf1p. As the DTT concentration in incubation solutions containing rat
liver canalicular plasma membrane vesicles was gradually decreased, ATP-dependent GSH transport was now detected.
These results demonstrate that Ycf1p and Mrp2 are inhibited by concentrations of reducing agents that are normally
employed in studies of GSH transport. When this inhibition was partially relieved, ATP-dependent GSH transport was
detected in rat liver canalicular plasma membranes, indicating that both Mrp2 and Ycf1p are able to transport GSH by an
ATP-dependent mechanism. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Reduced glutathione (GSH) is the major cellular
reductant, and plays an important role in protection
against toxic chemicals [1,2]. GSH is synthesized in
the cell cytosol, but is eventually exported across the
plasma membrane for degradation in the extracellu-
lar space [3^5]. Although GSH-speci¢c plasma mem-
brane transporters have not been identi¢ed, GSH is a
0005-2736 / 02 / $ ^ see front matter ß 2002 Elsevier Science B.V. All rights reserved.
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Abbreviations: LME, L-mercaptoethanol; cLPM, canalicular
liver plasma membrane; DNP-SG, S-(2,4-dinitrophenyl)gluta-
thione; DTE, dithioerythritol ; DTT, dithiothreitol ; GSH, re-
duced glutathione; GSSG, glutathione disul¢de
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substrate for the organic anion transporting polypep-
tides Oatp1 and Oatp2 [6,7], the multidrug resis-
tance-associated proteins Mrp1 and Mrp2 [8^21],
and the yeast orthologue of these Mrp proteins, the
vacuolar membrane transport pump Ycf1p [22,23].
Mammalian Mrp1 and Mrp2, and Ycf1p of the bud-
ding yeast Saccharomyces cerevisiae are ATP-binding
cassette (ABC) proteins that export organic anions,
including glutathione S-conjugates, concomitant with
ATP hydrolysis. These proteins have a similar sub-
strate speci¢city, although there appears to be a dif-
ference in their ability to transport GSH. GSH is a
low-a⁄nity ATP-dependent substrate for Ycf1p
[22,23], whereas studies in mammalian Mrp1- or
Mrp2-containing plasma membrane vesicles have
failed to detect ATP-dependent GSH transport ([8],
for review). The reason for this apparent discrepancy
between the yeast and mammalian Mrp orthologues
is unclear, but some possibilities have recently been
described [8,20], including: (a) a relatively high non-
speci¢c permeability of rat liver vesicles when com-
pared with yeast secretory vesicles, which tends to
dissipate solute gradients; (b) a high ATP hydrolysis
rate in liver plasma membrane vesicles, which leads
to the rapid depletion of the driving force for trans-
port; and (c) a relatively low catalytic e⁄ciency of
GSH transport in rat liver membrane vesicles (i.e. a
high Km and only modest Vmax).
The present study identi¢ed another factor that
contributes to the inability to detect ATP-dependent
GSH transport in liver membrane vesicles, namely
the inhibitory e¡ect of dithiothreitol (DTT), the re-
ducing agent that is normally added to prevent GSH
oxidation. Because all previous studies of GSH trans-
port have utilized high concentrations of reducing




[glycine-2-3H]GSH (0.982 Ci/mmol) and [G-3H]-
taurocholate (2.1 Ci/mmol) were purchased from
DuPont NEN. [glycine-2-3H]S-Dinitrophenyl gluta-
thione (DNP-SG) was synthesized as previously de-
scribed [24]. Zymolyase-100T was purchased from
Seikagaku America (Rockville, MD, USA). All other
chemicals and reagents were purchased from Sigma-
Aldrich, Amersham, J.T. Baker, or Fisher. The pH
of incubation solutions containing high concentra-
tions of GSH or other anions was routinely adjusted
to 7.5 immediately before use with Tris base.
2.2. Yeast strain and vacuole isolation
DTY165 (MATK ura3-52 his6 leu2-3,-112 his3-
v200 trp1-901 lys2-801 suc2-v) yeast strain of S. ce-
revisiae was kindly provided by Dennis Thiele (Uni-
versity of Michigan) and grown in YPD medium as
described by Li et al. [25,26]. Vacuolar membranes
were prepared and characterized according to meth-
ods described previously [22,23]. Vesicles were resus-
pended and stored at 380‡C in bu¡er containing 10
mM HEPES, pH 7.5, 250 mM sucrose, and 20 mM
KCl.
2.3. Rat canalicular liver plasma membrane
(cLPM) vesicles
Male Sprague^Dawley rats (V250 g) were ob-
tained from Charles River Laboratories (Kingston,
NY, USA) and fed Purina chow (formula 5001) ad
libitum. The methods used to isolate and characterize
cLPM were as described by Meier et al. [27] and
previously performed in this laboratory [24,28]. The
cLPM fraction contains vesicles that are both in the
right-side-out (V80%) and inside-out (V20%) con-
¢guration [29]. For the inside-out vesicles, the extra-
vesicular membrane face corresponds to the cytosolic
surface in vivo. Vesicles were resuspended and stored
at 380‡C in bu¡er containing 10 mM HEPES, pH
7.5, 250 mM sucrose, and 20 mM KCl.
2.4. Transport assays
Transport was measured as uptake of radiolabeled
substrate into vesicles collected by rapid ¢ltration on
Millipore 0.45 Wm ¢lter under vacuum, essentially as
described previously [24]. Membrane vesicles were
thawed by immersion in a 30‡C water bath and di-
luted in transport bu¡er (10 mM HEPES, pH 7.5,
250 mM sucrose, 20 mM KCl, with an ATP regen-
erating system consisting of 10 mM phosphocreatine,
10 mM MgCl2, 100 Wg/ml creatine phosphokinase,
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and either 5 mM Na2ATP or 10 mM NaCl). Diluted
vesicles were treated with 0.5 mM acivicin to inhibit
resident Q-glutamyl transpeptidase enzyme, passed re-
peatedly through a 26 g needle (U10), and incubated
at 30‡C for 15 min prior to starting the transport
reaction.
To minimize GSH oxidation in GSH transport
assays without DTT, we reduced the amount of dis-
solved oxygen in our transport bu¡er by saturating
the vacuum-degassed transport reaction solutions
with N2 for 30 min before initiating reaction incuba-
tions, and all incubations were done under nitrogen.
An enzymatic conversion of glutathione disul¢de
(GSSG) to GSH was also utilized in which we added
0.125 mg of glutathione reductase and 0.25 mM
NADPH to the transport reaction bu¡er. Transport
was started by adding 20 Wl of diluted membrane
vesicles to 80 Wl of incubation transport reaction
bu¡er (with substrate) at 4‡C or 30‡C for timed in-
tervals. Initial rates were determined where uptake
was linear with time at each substrate concentration
tested. Transport was quenched by adding 1 ml of
ice-cold stop bu¡er (300 mM sucrose, 10 mM
HEPES^Tris, pH 7.5, 20 mM KCl), and vesicles col-
lected by applying 1 ml of quenched reaction solu-
tion to a prewetted ¢lter under vacuum and washing
the ¢lter with an additional 4 ml of ice-cold stop
bu¡er. Filters were collected, dissolved in 5 ml of
Opti-Fluor (Packard Instrument, Meriden, CT,
USA), and radiolabeled drug uptake measured by
liquid scintillation counting. Controls for nonspeci¢c
binding of drug to ¢lters and vesicles were performed
by measuring retention of radiolabeled substrate on
¢lters in the absence of vesicles and in vesicles incu-
bated in transport bu¡er at 4‡C for each time point.
2.5. Determination of GSH and GSSG concentrations
The concentrations of GSH and GSSG were mea-
sured in transport reaction bu¡ers under conditions
used to measure transport of GSH by an enzymatic
procedure using glutathione reductase and 5,5P-di-
thio-bis(2-nitrobenzoic acid), either with or without
derivatization of GSH with 1 Wl of 2-vinylpyridine
[30,31].
2.6. Statistical analysis
Kinetic data from experiments measuring initial
rates of uptake of radiolabeled substrate in vacuolar
vesicles were ¢t to the Michaelis^Menten equation by
nonlinear least squares regression analysis using Sig-
maPlot 4.16. Vmax and Km values with standard er-
rors were derived from these curves. Comparison of
data measuring initial rates of uptake of [3H]DNP-
SG or [3H]GSH in the presence and absence of in-
hibitors was performed by paired Student’s t-test,
and correlated to P6 0.05.
3. Results
3.1. Reducing agents inhibit ATP-dependent
DNP-SG, but not taurocholate uptake in yeast
vacuolar membrane vesicles
The vacuolar membrane of S. cerevisiae contains
the ABC proteins Ycf1p, which can transport gluta-
thione S-conjugates such as DNP-SG [23,25,26], and
Bat1p, which can transport bile acids such as taur-
ocholate [32]. Transport by both proteins is ATP-de-
pendent. Examination of the initial rates of 10 WM
[3H]DNP-SG uptake in S. cerevisiae vacuolar plasma
membrane vesicles demonstrated that transport was
inhibited by DTT (Fig. 1). A DTT concentration of
0.1 mM had no e¡ect (data not shown), but trans-
Fig. 1. Reducing agents inhibit the initial rate of ATP-depen-
dent DNP-SG uptake in yeast vacuolar membrane vesicles. The
initial rate of ATP-dependent uptake of 10 WM [3H]DNP-SG in
S. cerevisiae DTY165 vacuolar plasma membrane vesicles was
measured in the presence of increasing concentrations of DTT
(a), DTE (b), or LME (P). The data points represent the
mean with standard errors of the di¡erences between uptake
measurements with 5 mM MgATP and those without ATP for
each condition of at least three experiments.
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port was signi¢cantly reduced at DTT concentrations
of 0.3 mM and higher (Fig. 1). Comparable results
were obtained when DTT was replaced with two
other sulfhydryl-reducing agents, dithioerythritol
(DTE) or L-mercaptoethanol (LME) (Fig. 1). Each
of these reducing agents showed statistically signi¢-
cant inhibition of ATP-dependent [3H]DNP-SG
transport at concentrations of 1 mM and higher.
ATP-dependent uptake of 0.1 mM [3H]GSH in
yeast vacuolar membrane vesicles was also inhibited
by DTT (Fig. 2). Note that the e¡ects of DTT on
DNP-SG and GSH transport were quantitatively
similar, supporting the conclusion that both com-
pounds are substrates for Ycf1p. In contrast, DTT
had only minimal e¡ects on ATP-dependent 10 WM
[3H]taurocholate transport (Fig. 2), indicating that
DTT’s e¡ects on Ycf1p-mediated transport are not
due to a generalized e¡ect on vesicle transport activ-
ity nor to a nonspeci¢c change in membrane integ-
rity.
3.2. Kinetics of DTT inhibition of ATP-dependent
[3H]DNP-SG transport in yeast vacuolar
membrane vesicles
The mechanism of action of DTT on Ycf1p was
examined by measuring the kinetics of [3H]DNP-SG
uptake with either 0, 1, 5, or 10 mM DTT (Fig. 3).
ATP-dependent uptake for each condition was ¢t to
the Michaelis^Menten equation, and the data are
presented as a Wol¡^Augustinsson^Hofstee plot
(Fig. 3, inset). The kinetic constants derived from
this analysis are presented in Table 1. The Ycf1p
apparent Km for DNP-SG was 39 WM with a Vmax
of 9 nmol (mg protein)31 min31. The apparent a⁄n-
ity for DNP-SG was not signi¢cantly changed by
DTT, whereas the Vmax values were markedly re-
duced as the DTT concentration was increased.
These data suggest that DTT inhibits Ycf1p-medi-
ated transport of [3H]DNP-SG in a noncompetitive
manner, and therefore is presumably not a¡ecting
substrate binding.
Because ATP is also a substrate for Ycf1p, we also
Fig. 2. E¡ects of DTT on the ATP-dependent uptake of DNP-
SG, taurocholate, and GSH in yeast vacuolar membrane
vesicles. The e¡ect of increasing concentrations of DTT on the
initial rate of ATP-dependent uptake of 10 WM [3H]DNP-SG
(a), 10 WM [3H]taurocholate (b), and 0.1 mM [3H]GSH (P)
was measured in vacuolar plasma membrane vesicles. The dif-
ference in uptake with 5 mM MgATP and without ATP was
calculated to be the ATP-dependent transport. Data points rep-
resent the mean with standard errors of three experiments.
Fig. 3. DTT noncompetitively inhibits Ycf1p-mediated transport
of DNP-SG in yeast vacuolar membrane vesicles. The e¡ects of
0 (a), 1 (b), 5 (P), and 10 mM DTT (S) on the initial rate of
ATP-dependent uptake of increasing concentrations of
[3H]DNP-SG were examined in yeast vacuolar membrane
vesicles. The data points represent the mean with standard er-
rors of at least three experiments. The data were ¢t by a least
squares linear regression curve that followed the Michaelis^
Menten equation (P6 0.05) to derive kinetic parameters. The
data were further analyzed by a Woolf^Augustinsson^Hofstee
plot to illustrate the kinetics of inhibition (inset).
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examined the e¡ect of 0, 1, 5, and 10 mM DTT on
the ATP concentration-dependent initial rate of up-
take of 10 WM [3H]DNP-SG (Fig. 4 and Table 1).
The Ycf1p apparent Km for ATP was 0.51 mM and
the Vmax was 0.36 nmol (mg protein)31 min31 in the
absence of DTT. DTT decreased the Vmax, but had
no signi¢cant e¡ect on the Km for MgATP (Fig. 4
and Table 1). These results indicate that DTT does
not a¡ect the transporter’s relative a⁄nity for ATP,
but rather inhibits the transporter at some allosteric
site distinct from both the ATP binding and sub-
strate binding sites.
3.3. DTT also inhibits ATP-dependent transport of
DNP-SG in rat cLPM vesicles
In support of the conclusions reached in the yeast
vacuolar membranes, uptake of 10 WM [3H]DNP-SG
by rat cLPM vesicles was also diminished by DTT,
whereas [3H]taurocholate transport was not a¡ected
(Fig. 5), indicating that Mrp2 is inhibited by DTT,
whereas the liver bile salt transporter (Bsep) is not.
The ATP-independent components of DNP-SG and
taurocholate uptake were small relative to the ATP-
dependent components, and were only minimally af-
fected by DTT.
3.4. Demonstration of ATP-dependent GSH transport
in rat cLPM vesicles when the
DTT concentration is decreased
To examine the e¡ects of DTT on ATP-dependent
GSH transport in rat cLPM vesicles, assay condi-
tions had to be established that would keep GSH
in the reduced form in the nominal absence of
DTT. It is critical to prevent oxidation of GSH to
GSSG, as the latter compound is a known substrate
for Mrp2 (and Ycf1p). To accomplish this, the trans-
port bu¡ers were degassed under vacuum with vigo-
rous stirring for 30 min at room temperature, and
were then bubbled with N2 for an additional 30 min.
All subsequent transport reactions were done under
Table 1
Kinetic parameters of ATP-dependent transport of DNP-SG by
Ycf1p
[DTT] (mM) Km (WM) Vmax (nmol mg31 min31)
A. Increasing [3H]DNP-SG] with 5 mM MgATP
0 39 þ 2 9.12 þ 0.45
1 28 þ 8 7.00 þ 0.06*
5 40 þ 7 5.70 þ 0.24*
10 44 þ 6 4.80 þ 0.04*
B. 10 WM [3H]DNP-SG with increasing [MgATP]
0 509 þ 60 0.36 þ 0.02
1 487 þ 140 0.31 þ 0.03
5 444 þ 70 0.24 þ 0.01*
10 855 þ 320 0.13 þ 0.02*
The initial rates of ATP-dependent uptake of increasing concen-
trations of [3H]DNP-SG with 5 mM MgATP (A), or 10 WM
[3H]DNP-SG with increasing concentrations of MgATP (B)
were measured in the presence of 0, 1, 5, 10 mM DTT. The ki-
netic parameters for these transport reactions were derived
from data in Figs. 3 and 4. Values represent the mean þ S.E.M.
of three experiments. *Signi¢cantly di¡erent from control,
P6 0.05.
Fig. 4. E¡ects of DTT on the kinetics of ATP concentration-de-
pendent uptake of DNP-SG in yeast vacuolar membrane
vesicles. The e¡ects of 0 (a), 1 (b), 5 (P), and 10 mM DTT
(S) on the initial rate of uptake of 10 WM [3H]DNP-SG with
increasing concentrations of MgATP were examined in yeast
vacuolar membrane vesicles. The data points represent the
mean with standard errors of at least three experiments. The
data were ¢t by a least squares linear regression curve that fol-
lowed the Michaelis^Menten equation (P6 0.05) to derive ki-
netic parameters. The data were further analyzed by a Woolf^
Augustinsson^Hofstee plot to illustrate the kinetics of inhibition
(inset).
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N2. The [3H]GSH stock was purchased as a 10 mM
DTT solution, and a 100 mM stock of GSH was
likewise prepared in 10 mM DTT using N2-saturated
water. The [3H]GSH and unlabeled GSH stocks were
diluted with oxygen-free bu¡ers to generate the de-
sired incubation solutions (i.e. 100 WM [3H]GSH with
0.1^10 mM DTT). The GSSG content in either the
concentrated GSH stock solutions or the diluted in-
cubation solutions was below the limits of our detec-
tion, 6 0.1 WM, for at least 90 min of incubation at
30‡C. Moreover, the addition of glutathione reduc-
tase with or without NADPH to the yeast vacuolar
membrane transport reactions had no e¡ect on ATP-
dependent uptake of radioactivity from [3H]GSH
(data not shown), also indicating the absence of
GSSG in these incubation solutions.
Using these experimental conditions, the uptake of
0.1 mM [3H]GSH by rat cLPM was measured with
and without 5 mM ATP, and in the presence of
either 10, 1, or 0.1 mM DTT (Fig. 6). In agreement
with the inhibitory e¡ect of DTT on DNP-SG trans-
port in cLPM vesicles (Fig. 5), DTT also inhibited
ATP-dependent GSH uptake (Fig. 6). The ATP-de-
pendent component of GSH uptake was minimal
when measured in the presence of 10 mM DTT
(Fig. 6A); however, when the DTT concentration
was lowered, the ATP-dependent component of up-
take increased, and it became statistically signi¢cant
at a DTT concentration of 0.1 mM (Fig. 6C). Like-
wise, the ATP-independent component of GSH up-
take increased as DTT concentration was decreased,
indicating that this transport process is also sensitive
to DTT. However, the molecular nature of this ATP-
independent transport process is presently unknown.
4. Discussion
The major ¢nding from this study is the direct
Fig. 5. E¡ects of DTT on the ATP-dependent uptake of DNP-
SG and taurocholate in rat cLPM vesicles. The e¡ects of in-
creasing concentrations of DTT on the initial rate of ATP-de-
pendent uptake of 10 WM [3H]DNP-SG (a) and 10 WM
[3H]taurocholate (b) were measured in rat cLPM vesicles. The
di¡erence in the uptake after 1 min was expressed as a percent-
age of control. The control values for the initial rate of ATP-
dependent uptake of 10 WM [3H]DNP-SG and 10 WM
[3H]taurocholate were 17.5 and 125 pmol (mg protein)31
min31, respectively.
Fig. 6. E¡ects of DTT on the time course of GSH uptake in rat cLPM vesicles. The e¡ect of 10 mM (A), 1 mM (B), or 0.1 mM
DTT (C) on the uptake of 0.1 mM [3H]GSH was measured in 50 Wg of rat cLPM vesicles in the presence (b) and absence (a) of
5 mM MgATP for up to 2.5 min. The data points represent the mean with standard errors of three experiments.
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demonstration of ATP-dependent GSH transport in
Mrp2-containing rat liver canalicular membrane
vesicles. Detection of ATP-dependent GSH transport
activity was made possible only when it was realized
that DTT inhibits Mrp2 function. As the concentra-
tion of this reducing agent was decreased, the rate of
transport increased to a detectable level. Because this
reducing agent was used in all previous studies of
GSH transport on Mrp proteins, these studies prob-
ably underestimated, and in most cases failed to de-
tect a transport signal. DTT also inhibited Ycf1p-
mediated GSH and DNP-SG transport (Fig. 2), in-
dicating that our previously reported transport rates
in yeast vesicles are also an underestimate [22,23].
However, because the inhibition by DTT is most
likely noncompetitive in nature, the published Km
values for these Ycf1p-mediated transport processes
remain valid (i.e. a Km of 0.2 mM for DNP-SG and
of 15 mM for GSH).
It is important to point out that the ATP-depen-
dent GSH transport rate measured in rat cLPM
vesicles is quite low (Fig. 6), but this is to be expected
given the low catalytic e⁄ciency of GSH export. Pre-
vious studies suggest that the Km for GSH transport
is high (in the mM range), whereas the Vmax is only
modest [8,15,16,20]. Moreover, cLPM vesicles have a
relatively high nonspeci¢c permeability, which leads
to the dissipation of solute gradients, as well as a
rapid ATP hydrolysis rate, which leads to the loss
of the driving force [20,24,27,28]. In addition, be-
cause only a small fraction of cLPM vesicles are in
the inside-out con¢guration (V20% [29]), only a few
vesicles contribute to ATP-dependent GSH uptake.
A low GSH transport rate was also observed in pre-
vious studies with skate liver plasma membrane
vesicles [20], with yeast vacuolar membrane vesicles
[23], and in cells and membrane vesicles expressing
Mrp2 [15^21]. Thus, both vertebrate Mrp2 and yeast
Ycf1p are able to transport GSH in an ATP-depen-
dent fashion. This conclusion is consistent with the
observation that Mrp2-de¢cient rats fail to export
GSH into hepatic bile, and with other studies in in-
tact cell systems [15^21].
DTT, DTE, and LME inhibited Ycf1p-mediated
ATP-dependent transport of DNP-SG in yeast vac-
uolar membrane vesicles to an equivalent degree,
with 10 mM concentrations showing roughly 40%
inhibition. DTT produced a quantitatively similar in-
hibition of Ycf1p- and Mrp2-mediated, ATP-depen-
dent GSH transport. The latter experiments were
done under conditions were GSH oxidation to
GSSG was minimal (the GSSG concentration was
maintained below the detection limit of 0.1 WM).
This concentration of GSSG is 3 orders of magni-
tude lower than the published Km for GSSG trans-
port on MRP, V100 WM [33]. In contrast, no e¡ect
of DTT was seen on Bat1p-mediated ATP-dependent
taurocholate transport in these same yeast membrane
vesicles, indicating that DTT’s e¡ects are not due to
a generalized disruption of transport activity or
membrane integrity.
The mechanism of DTT’s inhibition of Ycf1p was
examined by kinetic analysis of the initial rates of
DNP-SG transport in the presence and absence of
several concentrations of DTT (Figs. 3 and 4). In
the absence of DTT, the apparent Km for DNP-SG
was 39 þ 2 WM and the Vmax was 9.12 þ 2 nmol (mg
protein)31 min31, and the apparent Km for ATP was
509 þ 60 WM and the Vmax was 0.36 þ 0.02 nmol (mg
protein)31 min31. The addition of 1, 5, or 10 mM
DTT had no signi¢cant e¡ect on the relative a⁄nity
(Km) for either DNP-SG or ATP, but it reduced the
maximum velocity (Vmax), consistent with a noncom-
petitive model of inhibition. Noncompetitive inhibi-
tion by DTT suggests that Ycf1p has at least one
thiol-sensitive residue, and that this residue is located
at a site distinct from the DNP-SG or ATP binding
pockets. Ycf1p contains 18 cysteine residues, but it is
presently unknown which of these residues are crit-
ical for function.
It had been previously shown that sulfhydryl-reac-
tive reagents such as N-ethylmaleimide and 5,5P-di-
thio-bis(2-nitrobenzoate) are potent inhibitors of
ATP-dependent DNP-SG transport in rat liver canal-
icular plasma membrane vesicles [34,35] and in hu-
man erythrocytes [36], suggesting that Mrp2-medi-
ated transport is regulated by critical cysteine
residues, and may require thiol/disul¢de exchange.
The inactivation of DNP-SG transport by 5,5P-di-
thio-bis(2-nitrobenzoate) was reversed by lengthy
treatment with 10 mM DTT, but was only partially
reversed when vesicles were pretreated with other
thiol-reactive compounds [35]. In contrast, the e¡ects
of N-ethylmaleimide, which forms a covalent adduct
with reduced sulfhydryl groups, were essentially irre-
versible [35]. The present results demonstrating inhi-
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bition by sulfhydryl-reducing agents provides sup-
port for the suggestion that Mrp2-mediated trans-
port may be regulated by thiol/disul¢de exchange.
This model predicts that transport activity should
be inhibited by agents that disrupt thiol-redox cy-
cling through either oxidation or reduction reactions.
Additional studies are needed to test this hypothesis,
and to evaluate the molecular nature and physiolog-
ical signi¢cance of the thiol-sensitive site(s) on Mrp2
and Ycf1p.
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